Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 1.00 |
| ▸ | F5 | P12259 | 3/20 | 0.66 |
| ▸ | BRSK2 | Q8IWQ3 | 3/20 | 0.66 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287034 | 0.90 | F10 (1.00) | F10F5BRSK2BRD4PDE7A | |
| SCHEMBL17287074 | 0.86 | F10 (1.00) | F10F5BRSK2PDE7A | |
| SCHEMBL18889471 | 0.84 | F10 (0.80) | F10F5BRSK2BRD4PDE7A | |
| SCHEMBL18909728 | 0.84 | F10 (0.73) | F10F5BRSK2PDE7A | |
| SCHEMBL18660292 | 0.83 | F10 (0.86) | F10F5BRSK2BRD4PDE7A | |
| SCHEMBL17287067 | 0.79 | F10 (1.00) | F10F5BRSK2 | |
| SCHEMBL18889477 | 0.78 | F10 (0.78) | F10F5BRSK2PDE7A | |
| SCHEMBL18660299 | 0.75 | F10 (1.00) | F10F5BRSK2 | |
| SCHEMBL18909828 | 0.73 | F10 (0.70) | F10F5BRSK2PDE7A | |
| SCHEMBL18660257 | 0.72 | F10 (0.88) | F10F5BRSK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147283-B1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR XA INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY LTD (CN) | 2022-08-17 | — | — | EP | claimed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | claimed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | claimed |
| EP-3147283-B1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR XA INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY LTD (CN) | 2022-08-17 | — | — | EP | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3147283-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | North China Pharmaceutical Company., Ltd. (CN) | 2017-03-29 | — | — | EP | disclosed |
| EP-3147283-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | North China Pharmaceutical Company., Ltd. (CN) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015176625-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | 南京明德新药研发股份有限公司 | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | F10 2/4885F5 5/4885BRSK2 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.